{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T17:01:59Z","timestamp":1771002119434,"version":"3.50.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2007,4,27]],"date-time":"2007-04-27T00:00:00Z","timestamp":1177632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2007,4,27]],"date-time":"2007-04-27T00:00:00Z","timestamp":1177632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Current Science Inc"],"published-print":{"date-parts":[[2007,5]]},"DOI":"10.1007\/s11906-007-0018-2","type":"journal-article","created":{"date-parts":[[2007,4,26]],"date-time":"2007-04-26T18:57:51Z","timestamp":1177613871000},"page":"98-105","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["The role of aldosterone in resistant hypertension: Implications for pathogenesis and therapy"],"prefix":"10.1007","volume":"9","author":[{"given":"Murray","family":"Epstein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Calhoun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,4,27]]},"reference":[{"key":"18_CR1","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/S0306-3623(96)00290-X","volume":"28","author":"R.H. Foster","year":"1997","unstructured":"Foster RH, MacFarlane CH, Bustamante MO: Recent progress in understanding aldosterone secretion. Gen Pharmacol 1997, 28:647\u2013651.","journal-title":"Gen Pharmacol"},{"key":"18_CR2","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1097\/00060793-199706000-00006","volume":"4","author":"P.J. Fuller","year":"1997","unstructured":"Fuller PJ: Aldosterone\u2019s effects and mechanism of action. Curr Opin Endocrinol Diabetes 1997, 4:218\u2013224.","journal-title":"Curr Opin Endocrinol Diabetes"},{"key":"18_CR3","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1007\/BF02170397","volume":"10","author":"J.A. Luetscher Jr","year":"1954","unstructured":"Luetscher JA Jr, Neher JP, Wettstein A: Isolation of crystalline aldosterone from the urine of a nephrotic patient. Experientia 1954, 10:456\u2013458.","journal-title":"Experientia"},{"key":"18_CR4","first-page":"1","volume":"24","author":"I.S. Edelman","year":"1968","unstructured":"Edelman IS, Fimognari GM: On the biochemical mechanism of action of aldosterone. Recent Prog Horm Res 1968, 24:1\u201344.","journal-title":"Recent Prog Horm Res"},{"key":"18_CR5","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1080\/07435808909039097","volume":"15","author":"B.C. Rossier","year":"1989","unstructured":"Rossier BC: Mechanisms of action of mineralocorticoid hormones. Endocr Res 1989, 15:206\u2013226.","journal-title":"Endocr Res"},{"key":"18_CR6","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s11906-000-0017-z","volume":"2","author":"D. Duprez","year":"2000","unstructured":"Duprez D, De Buyzere M, Rietzchel ER, Clement DL: Aldosterone and vascular damage. Curr Hypertens Rep 2000, 2:327\u2013334.","journal-title":"Curr Hypertens Rep"},{"key":"18_CR7","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B. Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999, 341:709\u2013717.","journal-title":"N Engl J Med"},{"key":"18_CR8","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1161\/01.HYP.33.1.232","volume":"33","author":"R. Rocha","year":"1999","unstructured":"Rocha R, Chander PN, Zuckerman A, et al.: Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 1999, 33:232\u2013237.","journal-title":"Hypertension"},{"key":"18_CR9","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1097\/00004872-200105000-00001","volume":"19","author":"M. Epstein","year":"2001","unstructured":"Epstein M: Aldosterone and the hypertensive kidney: its emerging role as a mediator of progressive renal dysfunction: a paradigm shift. J Hypertension 2001, 19:829\u2013842.","journal-title":"J Hypertension"},{"key":"18_CR10","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/1043-2760(94)90165-1","volume":"5","author":"M. Wehling","year":"1994","unstructured":"Wehling M: Non-genomic actions of steroid hormones. Trends Endocrinol Metab 1994, 5:347\u2013353.","journal-title":"Trends Endocrinol Metab"},{"key":"18_CR11","doi-asserted-by":"publisher","first-page":"3517","DOI":"10.1210\/jc.83.10.3517","volume":"83","author":"M. Wehling","year":"1998","unstructured":"Wehling M, Spes CH, Win N, et al.: Rapid cardiovascular action of aldosterone in man. J Clin Endocrinol Metab 1998, 83:3517\u20133522.","journal-title":"J Clin Endocrinol Metab"},{"key":"18_CR12","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1161\/01.HYP.25.1.117","volume":"25","author":"M. Christ","year":"1995","unstructured":"Christ M, Douwes K, Eisen C, et al.: Rapid non-genomic effects of aldosterone on sodium transport in rat vascular smooth muscle cells: involvement of the Na+\/H+ antiport. Hypertension 1995, 25:117\u2013123.","journal-title":"Hypertension"},{"key":"18_CR13","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1161\/01.RES.76.6.973","volume":"76","author":"M. Wehling","year":"1995","unstructured":"Wehling M, Neylon CB, Fullerton M, et al.: Non-genomic effects of aldosterone on intracellular calcium in vascular smooth muscle cells. Circ Res 1995, 76:973\u2013979.","journal-title":"Circ Res"},{"key":"18_CR14","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/BF00202262","volume":"73","author":"M. Wehling","year":"1995","unstructured":"Wehling M: Looking beyond the dogma of genomic steroid action: insights and facts of the 1990s. J Mol Med 1995, 73:439\u2013447.","journal-title":"J Mol Med"},{"key":"18_CR15","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1046\/j.1523-1755.1999.00674.x","volume":"56","author":"S. Ebata","year":"1999","unstructured":"Ebata S, Muto S, Okada K, et al.: Aldosterone activates Na+\/H+ exchange in vascular smooth muscle cells by non-genomic and genomic mechanisms. Kidney Int 1999, 56:1400\u20131412.","journal-title":"Kidney Int"},{"issue":"SupplN","key":"18_CR16","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1093\/eurheartj\/16.suppl_N.92","volume":"16","author":"J.P. Bonvalet","year":"1995","unstructured":"Bonvalet JP, Alfaidy N, Farman N, et al.: Aldosterone: intracellular receptors in human heart. Eur Heart J 1995, 16(Suppl N):92\u201397.","journal-title":"Eur Heart J"},{"key":"18_CR17","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/ajh\/7.1.100","volume":"7","author":"L. Kornel","year":"1994","unstructured":"Kornel L: Colocalization of 11\u03b2-hydroxysteroid dehydrogenase and mineralocorticoid receptors in cultured vascular smooth muscle cells. Am J Hypertens 1994, 7:100\u2013103.","journal-title":"Am J Hypertens"},{"key":"18_CR18","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1161\/01.RES.71.3.503","volume":"71","author":"M. Lombes","year":"1992","unstructured":"Lombes M, Oblin ME, Gasc JM, et al.: Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor. Circ Res 1992, 71:503\u2013510.","journal-title":"Circ Res"},{"key":"18_CR19","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1172\/JCI117269","volume":"93","author":"M. Young","year":"1994","unstructured":"Young M, Fullerton M, Dilley R, et al.: Mineralocorticoids, hypertension and cardiac fibrosis. J Clin Invest 1994, 93:2578\u20132583.","journal-title":"J Clin Invest"},{"key":"18_CR20","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/j.1749-6632.2002.tb04415.x","volume":"970","author":"R. Rocha","year":"2002","unstructured":"Rocha R, Funder JW: The pathophysiology of aldosterone in the cardiovascular system. Ann N Y Acad Sci 2002, 970:89\u2013100.","journal-title":"Ann N Y Acad Sci"},{"key":"18_CR21","doi-asserted-by":"publisher","first-page":"3871","DOI":"10.1210\/en.141.10.3871","volume":"141","author":"R. Rocha","year":"2000","unstructured":"Rocha R, Stier CT Jr, Kifor I, et al.: Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology. 2000, 141:3871\u20133878.","journal-title":"Endocrinology"},{"key":"18_CR22","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B. Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F, et al., for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309\u20131321.","journal-title":"N Engl J Med"},{"key":"18_CR23","doi-asserted-by":"publisher","first-page":"2848","DOI":"10.1161\/01.CIR.0000039328.33137.6C","volume":"106","author":"P. Lacolley","year":"2002","unstructured":"Lacolley P, Labat C, Pujol A, et al.: Increased carotid wall elastic modulus and fibronectin in aldosterone-salt-treated rats. Circulation. 2002, 106:2848\u20132853.","journal-title":"Circulation"},{"key":"18_CR24","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/sj.jhh.1000737","volume":"13","author":"F. Veglio","year":"1999","unstructured":"Veglio F, Molino P, Cat Genova G, et al.: Impaired baroreflex function and arterial compliance in primary aldosteronism. J Hum Hypertens 1999, 13:29\u201336.","journal-title":"J Hum Hypertens"},{"key":"18_CR25","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1159\/000078714","volume-title":"Kidney and Blood Pressure Regulation","author":"M. Epstein","year":"2004","unstructured":"Epstein M: Role of aldosterone blockade in the management of hypertension and cardiovascular disease. In Kidney and Blood Pressure Regulation. Edited by Suzuki H, Saruta T. Basel: Karger; 2004:90\u2013104. [Contributions to Nephrology; vol 143.]"},{"key":"18_CR26","doi-asserted-by":"publisher","first-page":"940","DOI":"10.2215\/CJN.00240106","volume":"1","author":"M. Epstein","year":"2006","unstructured":"Epstein M, Williams GH, Weinberger M, et al.: Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 2006, 1:940\u2013951.","journal-title":"Clin J Am Soc Nephrol"},{"key":"18_CR27","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1001\/jama.289.16.2073","volume":"289","author":"H.R. Black","year":"2003","unstructured":"Black HR, Elliott WJ, Grandits G, et al., for the CONVINCE Research Group: Principal results of the controlled onset verapamil investigation of cardiovascular end points (CONVINCE) trial. JAMA 2003, 289:2073\u20132082.","journal-title":"JAMA"},{"key":"18_CR28","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1524-6175.2002.02045.x","volume":"4","author":"W.C. Cushman","year":"2002","unstructured":"Cushman WC, Ford CE, Cutler JA, et al.: Success and predictors of blood pressure control in diverse North American settings: The Antihypertensive and Lipid-Lowering and Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens 2002, 4:393\u2013404.","journal-title":"J Clin Hypertens"},{"key":"18_CR29","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S0140-6736(97)05381-6","volume":"350","author":"J.A. Staessen","year":"1999","unstructured":"Staessen JA, Fagard R, Thijs L, et al., for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators: Randomized double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1999, 350:757\u2013764.","journal-title":"Lancet"},{"key":"18_CR30","doi-asserted-by":"publisher","first-page":"3369","DOI":"10.1210\/en.138.8.3369","volume":"138","author":"C.E. Gomez-Sanchez","year":"1997","unstructured":"Gomez-Sanchez CE, Zhou MY, Cozza EN, et al.: Aldosterone biosynthesis in the rat brain. Endocrinology 1997, 138:3369\u20133373.","journal-title":"Endocrinology"},{"key":"18_CR31","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1161\/01.CIR.0000129307.26791.8E","volume":"109","author":"M.K. Nishizaka","year":"2004","unstructured":"Nishizaka MK, Zaman MA, Green SA, et al.: Impaired endothelial-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism. Circulation 2004, 109:2857\u20132861.","journal-title":"Circulation"},{"key":"18_CR32","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.amjmed.2006.03.038","volume":"119","author":"M. Epstein","year":"2006","unstructured":"Epstein M: Aldosterone blockade: an emerging strategy for abrogating progressive renal disease. Am J Med 2006, 119:912\u2013919.","journal-title":"Am J Med"},{"key":"18_CR33","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1440-1681.1994.tb02519.x","volume":"21","author":"R.D. Gordon","year":"1994","unstructured":"Gordon RD, Stowasser M, Tunny TJ, et al.: High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 1994, 21:315\u2013318.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"18_CR34","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1161\/01.HYP.0000079505.25750.11","volume":"42","author":"L. Mosso","year":"2003","unstructured":"Mosso L, Carvajal C, Gonz\u00e1lez A, et al.: Primary aldosteronism and hypertensive disease. Hypertension 2003, 42:161\u2013165.","journal-title":"Hypertension"},{"key":"18_CR35","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1161\/01.HYP.0000040261.30455.B6","volume":"40","author":"D.A. Calhoun","year":"2002","unstructured":"Calhoun DA, Nishizaka MK, Zaman MA, et al.: High prevalence of primary aldosteronism among black and white subjects with resistant hypertension. Hypertension 2002, 40:892\u2013896.","journal-title":"Hypertension"},{"key":"18_CR36","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0272-6386(01)80117-7","volume":"37","author":"B.J. Gallay","year":"2001","unstructured":"Gallay BJ, Ahmad S, Xu L, et al.: Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am J Kidney Dis 2001, 37:699\u2013705.","journal-title":"Am J Kidney Dis"},{"key":"18_CR37","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1097\/00004872-200411000-00026","volume":"22","author":"I.K. Eide","year":"2004","unstructured":"Eide IK, Torjesen PA, Drolsum A, et al.: Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens 2004, 22:2217\u20132226.","journal-title":"J Hypertens"},{"key":"18_CR38","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/sj.jhh.1001554","volume":"17","author":"B. \u0160trauch","year":"2003","unstructured":"\u0160trauch B, Zelinka T, Hampf M, et al.: Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J Hum Hypertens 2003, 17:349\u2013352.","journal-title":"J Hum Hypertens"},{"key":"18_CR39","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1161\/01.HYP.0000016176.16042.2F","volume":"39","author":"S. Taler","year":"2002","unstructured":"Taler S, Textor SC, Augustine JE: Resistant hypertension: comparing hemodynamic management to specialist care. Hypertension 2002, 39:982\u2013988.","journal-title":"Hypertension"},{"key":"18_CR40","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S0895-7061(02)03260-0","volume":"16","author":"H.L. Blas\u00e9","year":"2003","unstructured":"Blas\u00e9 HL, Panagopoulos G, Michelis MF: Effectiveness of furosemide in uncontrolled hypertension in the elderly: role of renal profiling. Am J Hypertens 2003, 16:187\u2013193.","journal-title":"Am J Hypertens"},{"key":"18_CR41","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.amjhyper.2004.11.021","volume":"18","author":"J.J.P. Garg","year":"2005","unstructured":"Garg JJP, Elliott WJ, Folker A, et al., for the RUSH Hypertension Service: Resistant hypertension revisited: a comparison of 2 university-based cohorts. Am J Hypertens 2005, 18:619\u2013626.","journal-title":"Am J Hypertens"},{"key":"18_CR42","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1161\/01.HYP.0000203309.07140.d3","volume":"47","author":"M.E. Ernst","year":"2006","unstructured":"Ernst ME, Carter BL, Goerdt CJ, et al.: Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 2006, 47:353\u2013358.","journal-title":"Hypertension"},{"key":"18_CR43","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.1001\/jama.265.24.3255","volume":"265","author":"SHEP Cooperative Research Group","year":"1991","unstructured":"SHEP Cooperative Research Group: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991, 265:3255\u20133264.","journal-title":"JAMA"},{"key":"18_CR44","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1161\/01.CIR.82.5.1616","volume":"82","author":"The Multiple Risk Intervention Trial Research Group","year":"1990","unstructured":"The Multiple Risk Intervention Trial Research Group (MRFIT): Mortality rates after 10-1\/2 years for hypertensive participants in the Multiple Risk Factor Intervention Trial. Circulation 1990, 82:1616\u20131628.","journal-title":"Circulation"},{"key":"18_CR45","first-page":"791","volume":"9","author":"B.J. Materson","year":"1995","unstructured":"Materson BJ, Reda DJ, Cushman WC, et al., for the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents: Results of combination antihypertensive therapy after failure of each of the components. J Hum Hypertens 1995, 9:791\u2013796.","journal-title":"J Hum Hypertens"},{"key":"18_CR46","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1136\/bmj.281.6248.1101","volume":"281","author":"L.E. Ramsay","year":"1980","unstructured":"Ramsay LE, Silas JH, Freestone S: Diuretic treatment of resistant hypertension. BMJ 1980, 281:1101\u20131103.","journal-title":"BMJ"},{"key":"18_CR47","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S0895-7061(01)02342-1","volume":"15","author":"J. Ouzan","year":"2002","unstructured":"Ouzan J, P\u00e9rault C, Lincoff AM, et al.: The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens 2002, 15:333\u2013339.","journal-title":"Am J Hypertens"},{"key":"18_CR48","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S0895-7061(03)01032-X","volume":"16","author":"M.K. Nishizaka","year":"2003","unstructured":"Nishizaka MK, Zaman MA, Calhoun DA: Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003, 16:925\u2013930.","journal-title":"Am J Hypertens"},{"key":"18_CR49","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1016\/j.amjhyper.2005.06.010","volume":"18","author":"A. Mahmud","year":"2005","unstructured":"Mahmud A, Mahgoub M, Hall M, et al.: Does aldosterone-to-renin ratio predict the antihypertensive effect of the aldosterone antagononist spironolactone?\n                           Am J Hypertens 2005, 18:1631\u20131635.","journal-title":"Am J Hypertens"},{"key":"18_CR50","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1161\/01.HYP.0000179582.42830.1d","volume":"46","author":"C. Saha","year":"2005","unstructured":"Saha C, Eckert GJ, Ambrosius WT, et al.: Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. Hypertension 2005, 46:481\u2013487.","journal-title":"Hypertension"},{"key":"18_CR51","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.amjhyper.2005.11.016","volume":"19","author":"Y. Sharabi","year":"2006","unstructured":"Sharabi Y, Adler E, Shamis A, et al.: Efficacy of add-on aldosterone receptor blocker in uncontrolled hypertension. Am J Hypertens 2006, 19:750\u2013755.","journal-title":"Am J Hypertens"},{"key":"18_CR52","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","volume":"15","author":"M.H. Weinberger","year":"2002","unstructured":"Weinberger MH, Roniker B, Krause SL, et al.: Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 2002, 15:709\u2013716.","journal-title":"Am J Hypertens"},{"key":"18_CR53","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.ahj.2004.12.005","volume":"150","author":"M.H. Weinberger","year":"2005","unstructured":"Weinberger MH, White WB, Ruilope L-M, et al.: Effects of eplerenone versus losartan inpatients with low-renin hypertension. Am Heart J 2005, 150:426\u2013433.","journal-title":"Am Heart J"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-007-0018-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11906-007-0018-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-007-0018-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-007-0018-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T20:10:41Z","timestamp":1652904641000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11906-007-0018-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4,27]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["18"],"URL":"https:\/\/doi.org\/10.1007\/s11906-007-0018-2","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,4,27]]},"assertion":[{"value":"27 April 2007","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}